Yau MK - Search Results

1

Pathway-selective antagonism of proteinase activated receptor 2.

Suen JY, Cotterell A, Lohman RJ, Lim J, Han A, Yau MK, Liu L, Cooper MA, Vesey DA, Fairlie DP. Suen JY, et al. Among authors: yau mk. Br J Pharmacol. 2014 Sep;171(17):4112-24. doi: 10.1111/bph.12757. Epub 2014 Jul 2. Br J Pharmacol. 2014. PMID: 24821440 Free PMC article.

2

Mapping transmembrane residues of proteinase activated receptor 2 (PAR₂) that influence ligand-modulated calcium signaling.

Suen JY, Adams MN, Lim J, Madala PK, Xu W, Cotterell AJ, He Y, Yau MK, Hooper JD, Fairlie DP. Suen JY, et al. Among authors: yau mk. Pharmacol Res. 2017 Mar;117:328-342. doi: 10.1016/j.phrs.2016.12.020. Epub 2016 Dec 16. Pharmacol Res. 2017. PMID: 27993717

3

Toward drugs for protease-activated receptor 2 (PAR2).

Yau MK, Liu L, Fairlie DP. Yau MK, et al. J Med Chem. 2013 Oct 10;56(19):7477-97. doi: 10.1021/jm400638v. Epub 2013 Jul 30. J Med Chem. 2013. PMID: 23895492

4

Diet-induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism.

Lim J, Iyer A, Liu L, Suen JY, Lohman RJ, Seow V, Yau MK, Brown L, Fairlie DP. Lim J, et al. Among authors: yau mk. FASEB J. 2013 Dec;27(12):4757-67. doi: 10.1096/fj.13-232702. Epub 2013 Aug 20. FASEB J. 2013. PMID: 23964081

5

Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor 2.

Xu W, Lim J, Goh CY, Suen JY, Jiang Y, Yau MK, Wu KC, Liu L, Fairlie DP. Xu W, et al. Among authors: yau mk. J Chem Inf Model. 2015 Oct 26;55(10):2079-84. doi: 10.1021/acs.jcim.5b00500. Epub 2015 Oct 12. J Chem Inf Model. 2015. PMID: 26445028

6

Benzylamide antagonists of protease activated receptor 2 with anti-inflammatory activity.

Yau MK, Liu L, Lim J, Lohman RJ, Cotterell AJ, Suen JY, Vesey DA, Reid RC, Fairlie DP. Yau MK, et al. Bioorg Med Chem Lett. 2016 Feb 1;26(3):986-991. doi: 10.1016/j.bmcl.2015.12.048. Epub 2015 Dec 17. Bioorg Med Chem Lett. 2016. PMID: 26725028

7

Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).

Yau MK, Lim J, Liu L, Fairlie DP. Yau MK, et al. Expert Opin Ther Pat. 2016;26(4):471-83. doi: 10.1517/13543776.2016.1154540. Epub 2016 Mar 3. Expert Opin Ther Pat. 2016. PMID: 26936077 Review.

8

Biased Signaling by Agonists of Protease Activated Receptor 2.

Jiang Y, Yau MK, Kok WM, Lim J, Wu KC, Liu L, Hill TA, Suen JY, Fairlie DP. Jiang Y, et al. Among authors: yau mk. ACS Chem Biol. 2017 May 19;12(5):1217-1226. doi: 10.1021/acschembio.6b01088. Epub 2017 Mar 14. ACS Chem Biol. 2017. PMID: 28169521

9

A Potent Antagonist of Protease-Activated Receptor 2 That Inhibits Multiple Signaling Functions in Human Cancer Cells.

Jiang Y, Yau MK, Lim J, Wu KC, Xu W, Suen JY, Fairlie DP. Jiang Y, et al. Among authors: yau mk. J Pharmacol Exp Ther. 2018 Feb;364(2):246-257. doi: 10.1124/jpet.117.245027. Epub 2017 Dec 20. J Pharmacol Exp Ther. 2018. PMID: 29263243

10

Structure, function and pathophysiology of protease activated receptors.

Adams MN, Ramachandran R, Yau MK, Suen JY, Fairlie DP, Hollenberg MD, Hooper JD. Adams MN, et al. Among authors: yau mk. Pharmacol Ther. 2011 Jun;130(3):248-82. doi: 10.1016/j.pharmthera.2011.01.003. Epub 2011 Jan 26. Pharmacol Ther. 2011. PMID: 21277892 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49 results

Search Page

Filters